John Dwyer, Shannon Eagan and Adam Trigg Author Article on the Implications of In re. Rigel Pharmaceuticals Inc., Securities Litigation (Health Law Litigation)

John Dwyer and Shannon Eagan, partners in the Securities Litigation practice, and litigation associate Adam Trigg authored an article in Health Law Litigation on the implications of the Rigel Pharmaceuticals securities case that was argued before the Ninth Circuit Court of Appeals.  Cooley represented Rigel Pharmaceuticals. 

View the article here.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may have been generated with the assistance of artificial intelligence (AI) in accordance with our AI Principles, may be considered Attorney Advertising and is subject to our legal notices.